[8-K] MaxCyte, Inc. Reports Material Event

Rhea-AI Filing Summary

Form 8-K overview: On 25 June 2025, MaxCyte, Inc. ("the Company") filed a Current Report to disclose that it has applied to the London Stock Exchange to cancel admission of its common stock to trading on AIM. The filing designates the action as an "Other Event" under Item 8.01.

Key dates: The last day of AIM trading will be 25 June 2025, and the AIM delisting becomes effective at 7:00 a.m. U.K. time on 26 June 2025.

Continuing listing: The Company explicitly states that the AIM delisting "has no impact on the Company’s Nasdaq listing," and the shares will remain traded on the Nasdaq Global Select Market under ticker MXCT.

Additional disclosure items: No financial statements, earnings data, or major transactions are included. One exhibit (Ex. 104) accompanies the filing, containing the Inline XBRL cover page.

Implications disclosed: The filing is focused solely on the administrative change in listing status; it does not describe strategic rationale, cost implications, or future capital-markets plans. Investors trading on Nasdaq are unaffected according to the Company. U.K.-based investors will cease to have on-exchange access via AIM once the delisting takes effect.

Positive

• None.

Negative

• Delisting from AIM eliminates a secondary trading venue; last trading day on AIM is 25 June 2025.

Insights

Financial Analyst

TL;DR: Administrative AIM delisting; Nasdaq listing intact; neutral financial impact.

This 8-K triggers no earnings revisions, capital actions, or guidance changes. The Company keeps its primary U.S. listing and merely removes a secondary venue. Because the filing states that Nasdaq trading continues unchanged, liquidity for the bulk of shareholders should remain stable. No new financial metrics are offered; therefore, valuation and earnings outlooks remain as previously disclosed. I view the event as operationally neutral and unlikely to move the stock in isolation.

Corporate Governance Expert

TL;DR: Single-listing simplifies regulatory compliance; no governance red flags.

Maintaining dual compliance with both SEC and AIM rules can be costly and time-consuming. By cancelling AIM admission, MaxCyte narrows its reporting obligations to U.S. standards, potentially streamlining governance processes. The board followed proper disclosure protocols via a timely 8-K and provided exact effective dates. Absence of insider transactions or going-concern language indicates routine corporate housekeeping rather than distress. Overall governance implications are neutral-to-modestly positive, but impact on shareholders is limited per Company’s statement.

0001287098false00012870982025-06-252025-06-25

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): June 25, 2025

​

MaxCyte, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware		001-40674		52-2210438
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)

​

9713 Key West Avenue, Suite 400 Rockville, Maryland		20850
(Address of principal executive offices)	​	(Zip Code)

​

Registrant’s telephone number, including area code: (301) 944-1700

​

N/A

(Former name or former address, if changed since last report.)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value	​	MXCT	​	The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☒

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 8.01.Other Events.

On June 25, 2025, MaxCyte, Inc. (the “Company”) announced that it had applied to the London Stock Exchange plc (the “LSE”) to cancel its admission of the Company’s common stock (the “Shares”) to trading on the AIM market (“AIM”) of the LSE (the “AIM Delisting”). It is expected that the AIM Delisting will become effective from 7:00 a.m. U.K. time on June 26, 2025, such that the last date of trading of the Shares on AIM will be June 25, 2025. The AIM Delisting has no impact on the Company’s Nasdaq listing of the Shares, which will continue to trade on the Nasdaq Global Select Market under the ticker symbol MXCT.

​

Item 9.01.Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL Document)

​

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​
​	MaxCyte, Inc.
​	​
Date: June 25, 2025	By:	/s/ Douglas Swirsky
​	​	Douglas Swirsky
​	​	Chief Financial Officer

​

​

​

FAQ

When will MaxCyte (MXCT) delist from AIM?

The delisting becomes effective at 7:00 a.m. U.K. time on 26 June 2025.

What is the final trading day for MXCT shares on AIM?

The last day of trading on AIM is 25 June 2025.

Does the AIM delisting affect MaxCyte’s Nasdaq listing?

No. The filing states that the Nasdaq Global Select Market listing remains unchanged under ticker MXCT.

Which exhibit accompanies MaxCyte’s Form 8-K filing?

Exhibit 104: Cover Page Interactive Data File embedded within the Inline XBRL document.

Why did MaxCyte file under Item 8.01 of Form 8-K?

Item 8.01 covers “Other Events.” The Company used it to disclose the AIM delisting, which is not a financial statement item.